


In the Claims:

Please amend claims 3-8 and 10-11 as follows. Please add new claims 12 to 20.

1. (Original) A compound of formula (I):



wherein:

Y is phenyl, optionally substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl and halosubstituted C₁₋₆ alkyl;


R² is (CH₂)_mR³ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form an optionally substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R³ is an optionally substituted 4- to 8- membered non-aromatic heterocyclyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted straight or branched C₁₋₁₀ alkyl, a C₅₋₇ cycloalkenyl or R⁵;

R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, and SO₂Me;

R⁵ is



wherein p is 0, 1 or 2 and X is CH₂ or O;

R⁶ is methyl, chloro or CH_xF_n wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

R⁷ is OH, C₁₋₆alkoxy, NR^{8a}R^{8b}, NHCOR⁹, NHSO₂R⁹, SO_qR⁹;

R^{8a} is H or C₁₋₆alkyl;

R^{8b} is H or C₁₋₆alkyl;


R⁹ is C₁₋₆alkyl;

q is 0, 1 or 2;

or a pharmaceutically acceptable derivative thereof.

2. (Original) A compound as claimed in claim 1 wherein Y is a substituted phenyl.

3. (Currently Amended) ~~A compound as claimed in claim 1 wherein the compound is of formula (Ia):~~



~~wherein;~~

wherein;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl and halosubstituted C₁₋₆ alkyl;

R² is (CH₂)_mR³ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form a 4- to 8-membered non- aromatic ring selected from azetidiny, pyrrolidiny, morpholiny, piperiziny, piperidiny, tetrahydropyridiny, azapine, oxapine, azacyclooctany, azaoxacyclooctany and azathiacyclooctany any of which can be unsubstituted or substituted by one, two or three substituents selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, a hydroxy group, a cyano group, halo, sulfonyl group, methylsulfonyl, NR^{8a}R^{8b}, NHCOCH₃, (=O), and -CONHCH₃.


R³ is 2- or 3- azetidiny, oxetany, thioxetany, thioxetany-s-oxide, thioxetany-s,s-dioxide, dioxalany, pyrrolidiny, tetrahydrofurany, tetrahydrothiopheny, morpholiny, piperidiny, piperaziny, tetrahydropyrany, tetrahydrothiopyrany, thiomorpholiny, thiomorpholiny-s,s-dioxide, tetrahydropyridiny, azapine, oxapine, azacyclooctany, azaoxacyclooctany, azathiacyclooctany, oxacyclooctany, thiacyclooctany, a C₃₋₈ cycloalkyl group, a straight or branched C₁₋₁₀ alkyl, a C₅₋₇ cycloalkenyl or R⁵, any of which can be unsubstituted or substituted by one, two or three substituents selected from C₁₋₆

alkyl, C₁₋₆ alkoxy, a hydroxy group, a cyano group, halo, sulfonyl group, methylsulfonyl, NR^{8a}R^{8b}, NHCOCH₃, (=O), and -CONHCH₃;

R¹⁰ is selected from C₁₋₆ alkyl, halosubstitutedC₁₋₆ alkyl, C₁₋₆ alkoxy, a hydroxy group, a cyano group, halo, a C₁₋₆alkyl sulfonyl group, -CONH₂, -NHCOCH₃, -COOH, halosubstitutedC₁₋₆ alkoxy, SC₁₋₆alkyl and SO₂NR^{8a}R^{8b};

R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstitutedC₁₋₆ alkyl, COCH₃, and SO₂Me;

R⁵ is



wherein p is 0, 1 or 2 and X is CH₂ or O;

R⁶ is methyl, chloro or CH_xFn wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

R⁷ is OH, C₁₋₆alkoxy, NR^{8a}R^{8b}, NHCOR⁹, NHSO₂R⁹, SO_qR⁹;

R^{8a} is H or C₁₋₆alkyl;

R^{8b} is H or C₁₋₆alkyl;

R⁹ is C₁₋₆alkyl;

q is 0, 1 or 2; and

d is 0, 1, 2 or 3

or a pharmaceutically acceptable derivative thereof.

4. (Currently Amended) A compound as claimed in claim 1 ~~any one of claims 1 to 3~~ wherein R⁴ is C₁₋₆alkyl or hydrogen.

5. (Currently Amended) A compound as claimed in claim 1 ~~any one of claims 1 to 4~~ wherein R⁶ is CF₃.

6. (Currently Amended) A compound as claimed in claim 1 ~~or 3~~ selected from any one of Examples 1 to 265 or a pharmaceutically acceptable derivative thereof.

7. (Currently Amended) A compound as claimed in claim 1 ~~in any one of claims 1 to 6~~ nanoparticulate form.
8. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any one of claims 1 to 7 or a pharmaceutically acceptable derivative thereof.~~
9. (Original) A pharmaceutical composition as claimed in claim 8 further comprising a pharmaceutical carrier or diluent thereof.
10. (Currently Amended) A method of treating an ~~a human or~~ animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound ~~of formula (I)~~ as claimed in claim 1 ~~any one of claims 1 to 7 or a pharmaceutically acceptable derivative thereof.~~
11. (Currently Amended) A method of treatment as claimed in claim 10 wherein the condition is an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis ~~or renal disorder.~~
12. (New) The method as claimed in claim 10, wherein said animal is a human.
13. (New) The method as claimed in claim 11 wherein the pain is selected from inflammatory pain, visceral pain, cancer pain, neuropathic pain, lower back pain, muscular skeletal, post operative pain, acute pain and migraine.
14. (New) 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable derivative thereof.

15. (New) 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide.
16. (New) 2-(3-Chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclopentylmethyl-amide_or a pharmaceutically acceptable derivative thereof.
17. (New) 2-(3-Chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclopentylmethyl-amide.
18. (New) A pharmaceutical composition comprising 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide or a pharmaceutically acceptable derivative thereof.
19. (New) A pharmaceutical composition comprising 2-(3-chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclopentylmethyl-amide or a pharmaceutically acceptable derivative thereof.
20. (New) A method of treating an animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound selected from 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (tetrahydropyran-4-ylmethyl)-amide and 2-(3-chloro-4-fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclopentylmethyl-amide.
21. (New) The method as claimed in claim 20, wherein said animal is a human.
22. (New) The method as claimed in claim 20, wherein said condition is an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis.

23. (New) The method as claimed in claim 20, wherein the pain is selected from inflammatory pain, visceral pain, cancer pain, neuropathic pain, lower back pain, muscular skeletal, post operative pain, acute pain and migraine.